Study ID: C38072-AS-40105

Study Title

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Teva Identifier

C38072-AS-40105

ClinicalTrials.gov Identifier

NCT02937168

Study Status

Terminated

Trial Condition(s)

Asthma

Interventions

Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 50 Years

Trial Duration

May 8, 2017 - May 24, 2017

Phase

Phase 4

Study Type

Interventional